[1] |
LIANG Jiaqi, SHAO Rong, LIU Pengcheng, LI Ming, RENG Jingtian, TANG Ren, WANG Yue.
Characteristics of dear health care provider letters in Europe and America
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 275-278.
|
[2] |
XU Shungui, LIU Chunguang.
Survey of the Regulation System of OTC Drugs in the United States
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(2): 141-144.
|
[3] |
LIU Pengcheng, WANG Jiayu, CHEN Jinmin, WANG Minjiao, SHEN Mengqiu, LI Ming.
Pharmacovigilance Laws in Europe and America and Their Implications for China
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 877-882.
|
[4] |
WU Jianru, XIAO Xiao, LIU Xiaoyu, WANG Shu.
Epidemic Characteristics of First-time Drug Abuse and Influencing Factors of Synthetic Drug Abuse among Adolescents in Shenzhen
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 823-827.
|
[5] |
ZHU Lan, Shao Bo, XIA Dongsheng.
Selection and Switch-to-OTC of Chinese Patent Medicines in China
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 785-789.
|
[6] |
WU Jianru, XIAO Xiao, CHENG Bin, LIU Xiaoyu, WANG Ling, MAO Qiurong.
Inspiration of Drug Abuse Surveillance and Warning System of USA to China
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(1): 32-36.
|
[7] |
LI Dan.
Overview of Incentives for Rare Disease Drugs Research and Development in the United States and Enlightenment for China
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(6): 339-342.
|
[8] |
WANG Lei, Wang chun-xue.
Comparison of Blood Pressure, Pulse Pressure, Heart Rate and Adverse Reaction Between Different Dosage of Etomidate-induced Anesthesia in Adolescents
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(5): 313-316.
|
[9] |
DONG Duo ,WU Gui-zhi, WANG Tao, LIU Jia,XIONG Wei-yi,WANG Dan .
The Enlightens on Carrying out Reporting Responsibility of Manufactures in China from Reviewing the Post Marketing Surveillance System in US
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(10): 607-610.
|
[10] |
SONG Yang, YOU Xiao-min, ZONG Mao-mao, YANG Yue.
Research of How Traditional Chinese Medicine Can Be Registered as OTC Drug in USA
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(9): 547-551.
|
[11] |
ZHENG Ming-jie, XIA Dong-sheng.
Problem Analysis and Suggestion on Application Materials of OTC Switch
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(10): 618-622.
|
[12] |
XU Mei-ting,XUE Yun-li,YANG Yue.
American Consumer Behavior Studies in RX-OTC Switch and the Inspirations to Our Country
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(1): 34-37.
|
[13] |
TANG Ren, WANG Xiao-yan, YANG Yue .
Brief Introduction and Implication of the Package Leaflet Readability Guidelines of FDA and EMA
[J]. Chinese Journal of Pharmacovigilance, 2013, 10(8): 464-467.
|
[14] |
DONG Duo ,LIU Cui-li.
The Revelation of Study on Drug Manufacture Post Marketing Surveillance System in the United States
[J]. Chinese Journal of Pharmacovigilance, 2013, 10(8): 456-459.
|
[15] |
XIA Dong-sheng ,TIAN Chun-hua ,WANG Ao, SONG Qiu-jie, LI Lan, DU Xiao-xi.
The Probe into the Necessity of the Safety Monitoring of Over-the-Counter Drug in China
[J]. Chinese Journal of Pharmacovigilance, 2013, 10(2): 80-83.
|